What is King Pharmaceuticals's other investments?

King Pharmaceuticals (KG) reported other investments of $175.67M in Q1 2026.

What does other investments mean?

This category captures miscellaneous financial assets that do not fit into standard classifications like marketable securities or equity method holdings. It often includes private equity, real estate, or alternative asset classes held for long-term appreciation. Tracking this helps investors understand the diversification and risk profile of the company's non-core asset portfolio.

King Pharmaceuticals KG Other Investments

Other Investments at other companies

Arch Capital GroupACGL

$3.33B+15.3%

Selective Insurance GroupSIGI

$96.92M-1.5%

Reinsurance Group of AmericaRGA

$1.53B+17.8%

W.R. BerkleyWRB

$1.16B+40.1%

Greenlight Capital RE, Ltd.GLRE

$66.44M-9.3%

Skyward Specialty Insurance Group, Inc.SKWD

——

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherInvestments.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's other investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's other investments?: King Pharmaceuticals (KG) reported other investments of $175.67M in Q1 2026.
What does other investments mean?: This category captures miscellaneous financial assets that do not fit into standard classifications like marketable securities or equity method holdings. It often includes private equity, real estate, or alternative asset classes held for long-term appreciation. Tracking this helps investors understand the diversification and risk profile of the company's non-core asset portfolio.